AFIB Acutus Medical

Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium

Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium

CARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston. This abstract – including full study results - will be presented on Friday, February 3, 2023.

The AcQForce Flutter clinical study was submitted to the FDA as part of Acutus’ PMA submission for the AcQBlate Force Sensing Ablation Catheter, the only force-sensing ablation catheter with a gold tip electrode, and System. The irrigated gold tip ablation catheter has 4x thermal conductivity compared to platinum catheters, which allows for significantly more energy delivery at a lower temperature and requires less saline flow.1 This is the first PMA submission by Acutus and the first time the company is presenting at a Late-Breaking Clinical Trials session.

To learn more about Acutus Medical’s complete portfolio of diagnostic, access and therapy products, please visit .

References

1. Linhart M. et al., Superiority of Gold Compared to Platinum Tip Irrigated Catheter Ablation of the Pulmonary Veins and the Cavotricuspid Isthmus: A Randomized Study Comparing Tip Temperatures and Cooling Flow Requirements. J Cardiovasc Electrophysiol. 2012 Jul; 23(7): 717–21

About Acutus Medical

Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

About AF Symposium

The AF Symposium is an intensive three-day symposium that brings together the world's leading medical scientists to share, in a highly interactive environment, the most recent advances in the field of atrial fibrillation. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 28 years, the meeting has become a major scientific forum at which health care professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field.

Follow Acutus Medical on: , , and .

Investor Contact

Caroline Corner

415-202-5678

Media Contact

Peter Neems

442-232-6094



EN
29/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acutus Medical

 PRESS RELEASE

Acutus Medical Reports Full Year 2024 Financial Results

Acutus Medical Reports Full Year 2024 Financial Results CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restri...

 PRESS RELEASE

Acutus Medical Announces Operational Downsizing

Acutus Medical Announces Operational Downsizing CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, “Following an extensive strategic review by the Company’s Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products.” Takeo ...

 PRESS RELEASE

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial R...

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of bus...

 PRESS RELEASE

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial ...

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year, from $1.5 million in the same quarter last year.Operating expenses for continuing operations were $2.2 million, a reduction of 47% compared to the same period last year.Recorded $2.9 million in gain on sale of business,...

 PRESS RELEASE

Acutus Medical Reports First Quarter 2024 Financial Results

Acutus Medical Reports First Quarter 2024 Financial Results CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch